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 The Merriam-Webster dictionary defines medicine several ways, including: ―1) a - 
substance or preparation used in treating disease, b - something that affects well-being; and 2) a - 
- the science and art dealing with the maintenance of health and the prevention, alleviation, or 
cure of disease, b - the branch of medicine concerned with the nonsurgical treatment of 
disease.‖1  Relevant to this editorial and this edition of Progress in Cardiovascular Diseases, 
salient touchstones from the definition of medicine include treating disease, affecting well-being, 
maintenance of health, prevention and alleviation of disease, and non-surgical.  At this juncture, 
a primary threat to the health and wellbeing of the global population is the incidence and 
prevalence of chronic diseases as well as future projections, including cardiovascular, pulmonary 
and metabolic diseases, as well as several forms of cancer are leading concerns.
2-4
  To address 
the chronic disease burden successfully, there is a need to reformulate our approach to medicine, 
including what constitutes medicine, optimal therapeutic dosages and by whom and where it is 
administered.
5
 
The rise in chronic disease incidence and prevalence is paralleled by an unrelenting rise 
in an unhealthy living phenotype; central to his phenotype are physical inactivity, poor diet, and, 
now, to a lesser extent in some countries but continuing to be a significant concern, tobacco use.
6
  
Excess body weight is intricately related to physical inactivity and poor diet and is thus also a 
common characteristic of the unhealthy living phenotype.  In fact, a recent position statement by 
the American Association of Clinical Endocrinologists and the American College of 
Endocrinology has proposed new terminology, ―adiposity-based chronic disease‖, bringing new 
attention to the detrimental impact to excess body mass to one’s health.7  There is broad 
recognition that a lifelong adoption of the healthy living phenotype (i.e., primordial prevention) 
or reversal of the unhealthy living phenotype (i.e., primary and secondary prevention), even if the 
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reversal is only partial, portends profound health (i.e., decreased morbidity and mortality as well 
as improved function and quality of life) and economic (i.e., decreased utilization of the most 
costly aspects of health care – hospitalizations, surgical procedures, and prescription 
medications) benefits.
8-11
 Compared to individuals who emulate the poorest lifestyle 
characteristics, it has been found that those with an ideal healthy living phenotype demonstrate a 
≥45% reduction in chronic disease risk.9, 12, 13  Even in individuals genetically predisposed to 
chronic disease, the ideal healthy living phenotype remains highly protective.
13
  Truly there is no 
other drug or surgical procedure that can boast such risk reductions.  It is again important to 
stress that risk reduction is on a continual scale, with any movement away from the unhealthy 
living phenotype toward facets of a healthy living phenotype portending significant health 
benefits.  Suffice to say, taking 20 minute walks twice per week is preferable to no leisure time 
physical activity (PA) as is having 2 servings of fruits and vegetables per day compared to no 
daily servings.
8, 14
 This pragmatic approach should replace the traditional dichotomous, 
guidelines-based approach (i.e., all or nothing) and is well-suited to optimize the uptake of 
characteristics of the healthy living phenotype in a larger proportion of the global population, 
particularly those currently emulating the poorest unhealthy living phenotype.  From a 
population perspective, minimal movements towards the healthy living phenotype are projected 
to have significant benefits.
15
  While we should always strive for an ideal healthy living 
phenotype in all individuals, recognizing the importance of medicinal pragmatism (i.e., a two-
way health-related dialogue with the intent of finding practical solutions to a problem and 
ultimately a common truth) will undoubtedly increase the likelihood of adherence to a healthier 
lifestyle.   
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The clear line between health living and the profound reduction in the risk for chronic 
disease is irrefutable.
16, 17
  In fact, the best approach to addressing the chronic disease crisis is to 
promote the adoption of the healthy living phenotype.  In revisiting the definition of medicine 
(i.e., treating disease, affecting well-being, maintenance of health, prevention and alleviation of 
disease, and non-surgical), a clear case is made for the concept of healthy living medicine 
(HLM).  The concept of exercise as medicine has already been established and promoted for 
several years.
18, 19
  In fact, we have been aware of the medicinal power of exercise for 
centuries.
20
  However, this is a fragmented approach that does not capture the full potential and 
importance of HLM.  The overarching goal of HLM is to optimally prolong the healthspan, 
which can be defined as the number of years an individual is healthy and free from debilitating 
disease.
5, 21
  Being physically active, consuming nutritious and healthy food, not smoking and 
maintaining an appropriate body weight are all essential to the healthspan.  This is in sharp 
contrast to the concept of the lifespan, which exclusively speaks to the number of years an 
individual is alive without necessarily considering functional independence and quality of life.  
From an economics standpoint, a health system that focusses on promoting the healthspan as 
opposed to the lifespan is far more favorable.
22, 23
 
The framework for the essential elements of HLM is well-captured by Life’s Simple 7 
(LS7) put forth by the American Heart Association, consisting of 4 health behaviors (PA, diet, 
tobacco use, and body weight) and 3 health factors (cholesterol, blood pressure, blood sugar).
8
  
Moreover, practicing ideal LS7 health behaviors synergizes with more favorable health factors.  
There is abundant evidence linking a more favorable LS7 score, on a continual scale, and 
improved health outcome.
24, 25
  As such, LS7 serves as both a vital sign and healthy living 
polypill.
26
  All individuals should be prescribed this polypill, the ingredients of which are the 
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foundation of HLM.  As mentioned previously, to optimize adherence to HLM, a pragmatic 
approach to up-titration as well as variable dosages and ingredients that constitute the healthy 
living polypill should be considered.  Such an approach aligns with the concept of precision 
medicine
27
; the healthy living polypill can and should consider personal characteristics and 
likelihood for adherence.  Unlike traditional pharmacology, the healthy living polypill can be 
constituted with variable ingredients and dosages while maintaining significant therapeutic 
efficacy and virtually no side effect profile.  For example, a common approach to providing PA 
recommendations focus on the ideal exercise phenotype with little forethought into the PA level 
from which an individual is beginning their journey toward a healthy living phenotype.  For an 
individual who leads a sedentary lifestyle, considering the instantaneous adoption of an exercise 
program consisting of 150 minutes or more of moderate intensity exercise per week
28
 may seem 
unattainable.  Moreover, the literature clearly indicates that movement away from a sedentary 
lifestyle toward any level of increased PA portends significant health benefits.
24
  Thus, with 
respect to the healthy living polypill and HLM moving forward, we should consider a medicinal 
pragmatism approach; finding a common truth, which in this case being any mutually agreed 
upon adoption of the healthy living phenotype, an achievement that should always be celebrated.  
Moreover, as the pragmatic two-way communication continues, the health care provider and 
individual receiving care should continually strive for increased adoption of the healthy living 
phenotype.  Literature examining the relationship between the incremental improvement in LS7 
scores and improved health outcome aligns with this premise.
25
  
In conclusion, to best address the current chronic disease burden and future projections, 
there is broad recognition and acceptance for the need to reinvent how healthcare is delivered.  
There must be a shift away from reactionary care, waiting for a diagnosis of one or more chronic 
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diseases to be highly likely, due to entrenchment of an unhealthy living phenotype, or to in fact 
be diagnosed before care is initiated.  Preventing chronic disease and, ideally, associated risk 
factors (e.g., excess body mass, elevated blood pressure, cholesterol and blood sugar) from ever 
occurring is of paramount importance.  To ideally deliver HLM, what constitutes a ―health care‖ 
setting must change; parks, schools, and the workplace, for example, should all be considered 
clinical settings ideal for the delivery of HLM in the context of primordial and primary 
prevention.
29
  The traditional healthcare settings (i.e., hospitals and outpatient clinics) must also 
embrace the delivery of HLM to all patients receiving care.  Essentially, every individual on the 
planet is eligible for HLM and should receive an individualized healthy living polypill 
prescription. The stakeholders invested in and required for the successful delivery and uptake of 
HLM and the healthy living polypill must also be expanded.
30
  For example, a 4
th
 grade educator 
should be invested in HLM, dispensing the healthy living polypill to his/her students.  Significant 
consideration must be put into how traditional healthcare professionals (e.g., physicians, nurses, 
pharmacists, dentists and other allied health professionals) are uniformly trained to deliver HLM 
and dispense the healthy living polypill.  The ability to effectively harmonize communication 
between the health care provider and individual receiving care as well as leverage technology are 
also key considerations.  Lastly, there is a need for a strategic HLM research agenda, focused on 
continually improving the way HLM is delivered.  This edition of Progress in Cardiovascular 
Diseases will provide a blueprint for the new Healthy Living Healthcare System and address key 
considerations needed to ensure this new system is optimally effective. 
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